Press Release

Hera-MI launches subsidiary in the United States

Nantes, France - On June 10, 2020, **Hera-MI announces the creation of its subsidiary in the United States "Hera-MI Corp."**

Since November 2019, Hera-MI has been the first and the only French company to have obtained CE mark approval for a clinical decision support software in 2D and 3D mammography based on Artificial Intelligence.

After establishing partnerships and making sales in Europe and the Middle East, Hera-MI's objective is to set up a development strategy in the United States.

Hera-MI created its subsidiary in the United States in April 2020 and the operational launch of Hera-MI Corp. is planned for January 2021. Firstly, Hera-MI has established collaborations with American imaging centers specializing in breast cancer diagnosis in order to collect American 2D / 3D mammograms and thus consider the diversity of populations. Hera-MI's Breast-SlimView software will be FDA 510 (k) cleared by the end of 2020.

Hera-MI Corp. will be headquartered in the Indianapolis Chamber of Commerce (Indy Chamber) Building. Indeed, the company is fortunate to benefit from the significant support provided by the Indy Chamber, which facilitates its installation and exploration of collaborations with imaging centers in the region such as Indiana University School of Medicine, Indiana University Health and the Komen Tissue Bank at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Andrew Crecelius, Indy Chamber director of strategy and global initiatives said, "*We are delighted to have worked closely with Hera-MI to ensure that the company's leadership is effectively connected with potential research partners, prospective customers, and supportive industry associations. The life science and technology industries are growing and converging quickly in Indianapolis, and we want to make sure that companies have the support they need, when accessing the U.S. market through the Indianapolis region. We're confident that Hera-MI will have success in the United States as part of our collaborative community.*"

In addition, the installation of Hera-MI in the United States is materialized through its selection from more than 400 companies applying for the highly competitive program of the Houston Accelerator MassChallenge. Hera-MI plans to open a second office in Houston in Q1 2021. Thanks to this program, Hera-MI aims to set up collaborative scientific projects with breast imaging centers in Texas. By participating in this accelerator, Hera-MI will have access to industry experts, a tailored program to the best partner companies and up to $ 500,000 in brand name deals. Learn more about this program.

About Hera-MI

Hera-MI is a French company founded in April 2017 and based in Nantes. The goal of Hera-MI is to use Artificial Intelligence to improve the early detection of breast cancer in order to offer better chances of recovery for patients and thus save millions of women worldwide.

Hera-MI has developed Breast-SlimView, a patented decision support software for 2D and 3D mammography. Breast-SlimView offers an innovative and disruptive reading support where only relevant information is displayed. Website: www.hera-mi.com.

Contacts
Media & Business:
Ludmilla Potiron / Lydia Behloul - Sales & Marketing Manager
sales@hera-mi.com

Investors:
Sylvie Davila - Founder & CEO
sylvie.davila@hera-mi.com

About Indiana University School of Medicine

Indiana University School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

About the Komen Tissue Bank

The Susan G. Komen Tissue Bank, a resource established by researchers at Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Indiana University School of Medicine and located in Indianapolis, is the world's only healthy breast tissue bank. It is uniquely positioned to characterize the molecular and genetic basis of normal breast development and compare it to the different types of breast cancer.